Mobia Medical, Inc. (NASDAQ:MOBI) Receives $20.25 Consensus PT from Brokerages

Mobia Medical, Inc. (NASDAQ:MOBI) has been assigned an average rating of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $20.25.

A number of equities analysts recently commented on the stock. Wall Street Zen raised shares of Mobia Medical from a “sell” rating to a “hold” rating in a research note on Sunday, June 14th. The Goldman Sachs Group initiated coverage on Mobia Medical in a research report on Tuesday, June 2nd. They set a “buy” rating and a $31.00 target price on the stock. Wolfe Research started coverage on Mobia Medical in a report on Tuesday, June 2nd. They issued an “outperform” rating on the stock. Zacks Research raised Mobia Medical to a “hold” rating in a research report on Wednesday, June 3rd. Finally, BTIG Research initiated coverage on Mobia Medical in a research note on Tuesday, June 2nd. They set a “buy” rating and a $19.00 price objective for the company.

Mobia Medical Stock Down 3.7%

Shares of MOBI stock opened at $10.72 on Wednesday. The stock has a fifty day moving average price of $12.78. The stock has a market cap of $356.43 million, a PE ratio of -0.56 and a beta of 2.84. Mobia Medical has a twelve month low of $10.19 and a twelve month high of $15.29.

Mobia Medical (NASDAQ:MOBI) last released its quarterly earnings data on Thursday, June 4th. The company reported ($19.30) earnings per share for the quarter. The company had revenue of $12.07 million for the quarter.

Insider Buying and Selling

In other news, Director Casey M. Tansey bought 66,666 shares of Mobia Medical stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $999,990.00. Following the completion of the acquisition, the director owned 233,332 shares of the company’s stock, valued at $3,499,980. This trade represents a 40.00% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Dana G. Jr. Mead purchased 7,000 shares of the stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $15.00 per share, for a total transaction of $105,000.00. Following the completion of the acquisition, the director directly owned 7,000 shares in the company, valued at approximately $105,000. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 1,273,332 shares of company stock valued at $19,088,930 over the last three months.